Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies

Xu, Bo; Shao, Zhimin; Wang, S; Jiang, Zefei; Hu, Xin; Zhang, X; X, Li; Liu, Jing; M, Li

doi:10.21147/j.issn.1000-9604.2018.03.05

Cited by 4 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a growing body of research showed a declining use of ABC, it is still widely prescribed. The results of a previous pooled analysis of four observational studies demonstrated that 61.9% of the early‐stage breast cancer were treated with ABC together with docetaxel, and our results are consistent with these ones 16 …”

Section: Discussionsupporting

confidence: 91%

Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study

Guo

Wang

et al. 2021

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

Background Anthracycline‐based chemotherapy (ABC) is one of the standard therapies against breast cancer. However, few guidelines are currently available to optimize the use of ABC. Therefore, the present analysis aimed at determining the profile and treatment patterns of ABC and the association of clinicopathological characteristics with ABC selection. Methods We retrospectively analyzed the data of a nation‐wide multicenter epidemiological study, which collected the medical records of breast cancer patients receiving chemotherapy in different settings from seven geographic regions in China (NCT03047889). Results In total, 3393 patients were included, with 2917 treated with ABC. Among them, 553 (89.8%), 2165 (81.7%), and 814 (25.7%) were subjected to ABC as neoadjuvant, adjuvant, and advanced chemotherapy, respectively. The most frequently used regimens were anthracycline‐taxane‐based combinations for neo‐ and adjuvant chemotherapy, along with taxanes and oral fluorouracils for the palliative stages. In the overall cohort, patients aged < 40 or 40‐65 (p < 0.001), in premenopause (p < 0.001), without comorbidities (p = 0.016), with invasive ductal carcinoma (p= 0.001), high lymph node involvement (p < 0.001), in the pTNM stage II, III, or IV versus stage I (p < 0.001), subjected to mastectomy (p < 0.001) or subjected to sentinel lymph node biopsy combined with axillary lymph node dissection (p = 0.044), or with a decreased disease‐free survival (p < 0.001) were more likely to be recommended to ABC. Conclusion Taken together, ABC remained the mainstay of breast cancer treatment, especially in neo and adjuvant therapy. ABC was mainly used as a combination therapy, and the correlation between influencing factors and ABC choice varied during different settings, indicating the preference and different perspectives of medication considered by medical oncologists regarding the use ABC in China.

show abstract

Section: Discussionsupporting

confidence: 91%

Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study

Guo

Wang

et al. 2021

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neoadjuvant chemotherapy is a systemic and systemic oncology treatment prior to local breast cancer treatment; it reverses the clinical stage of cancer, inhibits tumor metastasis and resistance to cancer cell drugs, and provides drug sensitivity information and a basis for a rational chemotherapy regimen selection after surgery. A previous clinical trial suggested that neoadjuvant chemotherapy with epirubicin plus docetaxel improved the treatment outcome in breast cancer patients [11].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of epirubicin plus docetaxel or paclitaxel in the treatment of breast cancer

Zhu¹,

Gan²,

Sun³

et al. 2023

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To determine the clinical efficacy of epirubicin plus docetaxel or paclitaxel in the management of breast cancer. Methods: This study was a randomized controlled trial that recruited 78 patients with breast cancer treated in The First People’s Hospital of Anqing between December 2018 and March 2021. The participants were randomized to receive either epirubicin plus docetaxel (control group) or epirubicin plus paclitaxel (study group), with 39 cases in each group. Clinical outcomes, adverse events, quality of life, and prognosis of the two groups were compared. Results: Epirubicin plus paclitaxel produced greater efficacy than epirubicin plus docetaxel (p < 0.05). The combination also exhibited a higher safety profile versus epirubicin with docetaxel, as evidenced by lower incidences of nausea and vomiting, intestinal discomfort, muscle pain, and dyspnea reactions (p < 0.05). Epirubicin with paclitaxel resulted in greater improvement in quality of life in patients than epirubicin plus docetaxel (p < 0.05) as well as provided more benefits in terms of survival and recurrence control than epirubicin plus docetaxel (p < 0.05). Conclusion: Epirubicin/paclitaxel combination alleviates clinical symptoms, reduces adverse events, enhances patient prognosis, lowers the risk of postoperative recurrence, and provides superior quality of life when compared to epirubicin/docetaxel combination in breast cancer patients. Nonetheless, large-scale and better-randomized clinical trials are required to validate the findings of this study.

show abstract

“…Therefore, it is a common chemotherapy drug for the treatment of breast cancer clinically. 3,4 In the course of administration, he efficacy of this chemotherapy drug is largely limited by various factors. DOX, as a liposoluble compound, features low solubility and poor tissue specificity.…”

Section: Introductionmentioning

confidence: 99%

Construction of long-circulation EpCAM targeted drug delivery system and its application in the diagnosis and treatment of breast cancer

2020

View full text Add to dashboard Cite

Docetaxel (DOX) is usually one of drugs used for breast cancer treatment. The key of targeted drug delivery therapy is to deliver effective drugs directly and safely to the tumor focus via an efficient targeting drug carrier with immunogenicity. In this study, Long-circulating targeted drug carrying microspheres (DOX-PEG-EpCAM-MNs) entrapping DOX were constructed. In addition, both cytotoxicity and magnetic resonance imaging (MRI) analyses were performed to establish a mouse model and further complete corresponding performance analysis.The results showed that the average particle size of DOX-PEG-EpCAM-MNs was 139.3 ± 1.6 nm. Morphological analysis proves that they are spherical and uniformly dispersed. The Corresponding entrapment rate and drug carrying capacity are 82.43% and 7.16% respectively. Additionally, MRI shows that they have the capability to track tumor cells within 5 days. This study established a safe and efficient breast cancer cells targeted long-circulating drug delivery system.

show abstract

Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies

Abstract: Real-world data revealed that docetaxel/anthracycline combination is the most commonly used category of docetaxel-based adjuvant therapy for patients with operable breast cancer in China; of which TEC is the most frequently used regimen.

Cited by 4 publications

References 47 publications

Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study

Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study

Efficacy of epirubicin plus docetaxel or paclitaxel in the treatment of breast cancer

Construction of long-circulation EpCAM targeted drug delivery system and its application in the diagnosis and treatment of breast cancer

Contact Info

Product

Resources

About